Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial

Quantum Immunologics announces the completion of its first clinical treatment
injection

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa,
Florida company focusing on the research and development of cancer
immunotherapies, announces that the first patient in its breast cancer trial
has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II
clinical trial testing the safety and efficacy of its immunotherapy on 27
Stage IV breast cancer patients who have failed conventional therapy.
According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant
milestone in the life cycle of our company, and we look forward with great
hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the
oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a
cancer antigen (a protein found on cancer cells that can be targeted by the
body's own immune system) found in many tumor cell lines or fetal tissue, but
absent on normal, healthy tissue. QI believes that the OFA antigen can serve
as a unique, valuable and promising antigen for individualized breast cancer
immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's
proprietary dendritic cell therapy, which employs OFA to recruit the patient's
own immune system to target and attack the cancer cells with the intent to
improve patient survivability and quality of life. Each patient will receive
three monthly injections of the patient's own dendritic cells that have been
sensitized to OFA. It is anticipated that once the sensitized cells are
injected back into the patient, the patient's T-cells will locate the OFA
found on the patient's cancer cells, thereby generating an immune response
with the goal of killing the cancer cells and preventing further spread of the
disease.

About Quantum Immunologics

Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company
that is pioneering discoveries in immunotherapy science. QI is dedicated to
the research, development and production of technologies that focus on the
treatments and diagnoses of cancer and other diseases related to the immune
system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI
remains committed to advancing medicine with the ultimate goal of dramatically
improving lives.

For more information about QI and its FDA-authorized trials, please visit
http://www.quantumimmunologics.com, or contact Investor Relations at (813)
849-7859.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include, but are
not limited to, statements regarding product development, product potential or
financial performance. No forward-looking statement can be guaranteed and
actual results may differ materially from those projected. Quantum
Immunologics, Inc. undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events, or otherwise.
Contact:

Timothy Schwiers
Investor Relations
813-849-7859

Quantum Immunologics, Inc.
2202 N. West Shore Blvd., Suite 200
P.O. Box 20727
Tampa, Florida 33623

This release was issued through eReleases(TM). For more information, visit
http://www.ereleases.com.

SOURCE Quantum Immunologics, Inc.

Timothy Schwiers, Investor Relations, of Quantum Immunologics, Inc.,
+1-813-849-7859